NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

NABR: The U.S. Fish and Wildlife Service for the Second Time Rejects Activists' Petition to List Long-Tailed Macaque Monkeys Under the Endangered Species Act

WASHINGTON, July 14, 2026 /PRNewswire/ -- On July 14, 2026, the U.S. Fish and Wildlife Service ("USFWS") for the second time declined to accept a petition filed by People for the Ethical Treatment of Animals ("PETA") and other activist groups to...

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food...

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

The U.S. FDA Approved the Phase I/II Clinical Trial Application to Evaluate LBL-033, An Anti-MUC16/CD3 Bispecific Antibody Developed by Leads Biolabs, in Advanced Solid Tumors Including Ovarian Cancer

...

menu
menu